SCHEMBL3330209

SCHEMBL3330209

Cc1cc(-c2cc(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)[nH]c(=O)n2)ccc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.58
GSK3B P49841 2/20 0.58
CDC7 O00311 1/20 0.58
CSNK2A2 P19784 1/20 0.58
CLK1 P49759 1/20 0.58
CSNK2B P67870 1/20 0.58
CSNK2A1 P68400 1/20 0.58
CSNK2A3 Q8NEV1 1/20 0.58
CXCL12 P48061 1/20 0.54
MAPK14 Q16539 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 2/20 0.43
LMNA P02545 1/20 0.43
PPARA Q07869 1/20 0.42
SCN2A Q99250 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3332479 0.90 PIM1 (0.69) PIM1GSK3BCDC7CSNK2A2CLK1
SCHEMBL3330902 0.90 PIM1 (0.58) PIM1GSK3BCDC7CSNK2A2CLK1
SCHEMBL3329627 0.89 CDC7 (0.54) PIM1GSK3BCDC7CSNK2A2CLK1
SCHEMBL3334789 0.89 PIM1 (0.56) PIM1GSK3BCDC7CSNK2A2CLK1
SCHEMBL3330086 0.85 PIM1 (0.62) PIM1GSK3BCDC7CSNK2A2CLK1
SCHEMBL385566 0.85 CDC7 (0.79) PIM1GSK3BCDC7CSNK2A2CLK1
SCHEMBL3328710 0.84 PIM1 (0.58) PIM1GSK3BCDC7CSNK2A2CLK1
SCHEMBL3327715 0.84 PIM1 (0.57) PIM1GSK3BCDC7CSNK2A2CLK1
SCHEMBL3329490 0.83 GSK3B (0.56) PIM1GSK3BCDC7CSNK2A2CLK1
SCHEMBL3329595 0.82 PIM1 (0.57) PIM1GSK3BCDC7CSNK2A2CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242129-B2 6-phenylpyrimidinones as PIM modulators EXELIXIS, INC. (US) 2012-08-14 US claimed
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators EXELIXIS, INC. (US) 2010-06-03 US claimed
EP-2074103-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS Exelixis, Inc. (US) 2009-07-01 EP claimed
WO-2008133955-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS EXELIXIS, INC. (US) 2008-11-06 WO claimed
US-8242129-B2 6-phenylpyrimidinones as PIM modulators EXELIXIS, INC. (US) 2012-08-14 US disclosed
US-8242129-B2 6-phenylpyrimidinones as PIM modulators EXELIXIS, INC. (US) 2012-08-14 US disclosed
US-8242129-B2 6-phenylpyrimidinones as PIM modulators EXELIXIS, INC. (US) 2012-08-14 US disclosed
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2074103-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS Exelixis, Inc. (US) 2009-07-01 EP disclosed
WO-2008133955-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS EXELIXIS, INC. (US) 2008-11-06 WO disclosed
WO-2008133955-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS EXELIXIS, INC. (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators PIM1, PIM2, PIM3 PIM1 1/4885GSK3B 907/4885CDC7 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.